Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Evolution of Distinct Responses to Low NAD+ Stress by Rewiring the Sir2 Deacetylase Network in Yeasts.

Humphrey KM, Zhu L, Hickman MA, Hasan S, Maria H, Liu T, Rusche LN.

Genetics. 2020 Feb 18. pii: genetics.303087.2020. doi: 10.1534/genetics.120.303087. [Epub ahead of print]

2.

Telemedicine for Pediatric Urologic Postoperative Care is Safe, Convenient and Economical.

Finkelstein JB, Cahill D, Young K, Humphrey K, Campbell J, Schumann C, Nelson CP, Gupta A, Estrada CR Jr.

J Urol. 2020 Jan 17:101097JU0000000000000750. doi: 10.1097/JU.0000000000000750. [Epub ahead of print]

PMID:
31951495
3.

Demonstrating the value of postgraduate fellowships for physicians in quality improvement and patient safety.

Myers JS, Lane-Fall MB, Perfetti AR, Humphrey K, Sato L, Shaw KN, Taylor AM, Tess A.

BMJ Qual Saf. 2019 Dec 3. pii: bmjqs-2019-010204. doi: 10.1136/bmjqs-2019-010204. [Epub ahead of print]

PMID:
31796578
4.

Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.

Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D.

Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24.

PMID:
31549889
5.

Breaking down the silos of medical error.

Humphrey K, Brichko L, Cobbett J.

Emerg Med Australas. 2019 Aug;31(4):659-661. doi: 10.1111/1742-6723.13350. Epub 2019 Jul 10. No abstract available.

PMID:
31293081
6.

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).

Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow J, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V.

Am J Hematol. 2019 Sep;94(9):1002-1006. doi: 10.1002/ajh.25561. Epub 2019 Jul 8.

PMID:
31222797
7.

A Gender- and Culturally Sensitive Weight Loss Intervention for Hispanic Men: Results From the Animo Pilot Randomized Controlled Trial.

Garcia DO, Valdez LA, Aceves B, Bell ML, Humphrey K, Hingle M, McEwen M, Hooker SP.

Health Educ Behav. 2019 Oct;46(5):763-772. doi: 10.1177/1090198119853011. Epub 2019 Jun 19.

PMID:
31216875
8.

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.

Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D.

Clin Pharmacokinet. 2019 Dec;58(12):1621-1634. doi: 10.1007/s40262-019-00788-8.

PMID:
31209657
9.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M.

N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

PMID:
31166681
10.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

11.

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ.

Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12.

12.

Climate corrosion: Heroes wanted - Enquire within.

Tran V, Humphrey K, Cobbett J.

Emerg Med Australas. 2019 Apr;31(2):271-273. doi: 10.1111/1742-6723.13270. Epub 2019 Feb 26. No abstract available.

PMID:
30808070
13.

The Use of Telemedicine for the Postoperative Urological Care of Children: Results of a Pilot Program.

Finkelstein JB, Cahill D, Kurtz MP, Campbell J, Schumann C, Varda BK, Grant R, Humphrey K, Meyers H, Nelson CP, Estrada CR Jr.

J Urol. 2019 Jul;202(1):159-163. doi: 10.1097/JU.0000000000000109. Epub 2019 Jun 7.

PMID:
30707132
14.

Making the night shift the right shift.

Cobbett J, Brichko L, Humphrey K, Tran V.

Emerg Med Australas. 2019 Feb;31(1):117-119. doi: 10.1111/1742-6723.13232. Epub 2019 Jan 12. No abstract available.

PMID:
30635993
15.

Involvement of β-catenin in cytoskeleton disruption following adult neural stem cell exposure to low-level silver nanoparticles.

Cooper RJ, Menking-Colby MN, Humphrey KA, Victory JH, Kipps DW, Spitzer N.

Neurotoxicology. 2019 Mar;71:102-112. doi: 10.1016/j.neuro.2018.12.010. Epub 2018 Dec 31.

PMID:
30605761
16.

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ.

J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.

17.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.

18.

Establishing a role for environmental toxicant exposure induced epigenetic remodeling in malignant transformation.

Humphrey KM, Pandey S, Martin J, Hagoel T, Grand'Maison A, Ohm JE.

Semin Cancer Biol. 2019 Aug;57:86-94. doi: 10.1016/j.semcancer.2018.11.002. Epub 2018 Nov 16. Review.

PMID:
30453042
19.

Utility of Breast MRI for Further Evaluation of Equivocal Findings on Digital Breast Tomosynthesis.

Niell BL, Bhatt K, Dang P, Humphrey K.

AJR Am J Roentgenol. 2018 Nov;211(5):1171-1178. doi: 10.2214/AJR.17.18866. Epub 2018 Sep 12.

PMID:
30207789
20.

Microbial transmission in an outpatient clinic and impact of an intervention with an ethanol-based disinfectant.

Reynolds KA, Sexton JD, Pivo T, Humphrey K, Leslie RA, Gerba CP.

Am J Infect Control. 2019 Feb;47(2):128-132. doi: 10.1016/j.ajic.2018.06.017. Epub 2018 Sep 5.

21.

The ACEM Primary Examination: A foundation in flux.

Brichko L, Tran V, Cobbett J, Humphrey K.

Emerg Med Australas. 2018 Oct;30(5):709-711. doi: 10.1111/1742-6723.13167. Epub 2018 Sep 3. No abstract available.

PMID:
30175549
22.

MPP+ decreases store-operated calcium entry and TRPC1 expression in Mesenchymal Stem Cell derived dopaminergic neurons.

Sun Y, Selvaraj S, Pandey S, Humphrey KM, Foster JD, Wu M, Watt JA, Singh BB, Ohm JE.

Sci Rep. 2018 Aug 6;8(1):11715. doi: 10.1038/s41598-018-29528-x.

23.

Protected clinical support time should be a given: Yes.

Thampi A, Forbes J, Humphrey K.

Emerg Med Australas. 2018 Aug;30(4):569-570. doi: 10.1111/1742-6723.13138. Epub 2018 Jul 10. No abstract available.

PMID:
29987876
24.

Emergency medicine behind the scenes: Clinical support time.

Humphrey K, Brichko L.

Emerg Med Australas. 2018 Aug;30(4):564-566. doi: 10.1111/1742-6723.13139. Epub 2018 Jul 8. No abstract available.

PMID:
29984548
25.

Social media in medical education: How far have we come?

Cobbett J, Tran V, Humphrey K.

Emerg Med Australas. 2018 Jun;30(3):420-422. doi: 10.1111/1742-6723.13102. Epub 2018 May 6. No abstract available.

PMID:
29732689
26.

An Investigation of Drug-Drug Interaction Alert Overrides at a Pediatric Hospital.

Humphrey K, Jorina M, Harper M, Dodson B, Kim SY, Ozonoff A.

Hosp Pediatr. 2018 May;8(5):293-299. doi: 10.1542/hpeds.2017-0124.

27.

A gender- and culturally-sensitive weight loss intervention for Hispanic males: The ANIMO randomized controlled trial pilot study protocol and recruitment methods.

Garcia DO, Valdez LA, Bell ML, Humphrey K, Hingle M, McEwen M, Hooker SP.

Contemp Clin Trials Commun. 2018 Feb 9;9:151-163. doi: 10.1016/j.conctc.2018.01.010. eCollection 2018 Mar.

28.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP.

N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

29.

Evidence-based medicine: The significance of research literacy in emergency medicine training.

Brichko L, Forbes J, Humphrey K.

Emerg Med Australas. 2017 Dec;29(6):717-719. doi: 10.1111/1742-6723.12889. Epub 2017 Nov 3. No abstract available.

PMID:
29105321
30.

Hitting the ground running: Returning to work after extended leave.

Humphrey K, Hamilton S, Tran V.

Emerg Med Australas. 2017 Oct;29(5):578-580. doi: 10.1111/1742-6723.12851. Epub 2017 Aug 28. No abstract available.

PMID:
28845546
31.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M.

Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21. No abstract available. Erratum in: Blood. 2017 Jul 13;130(2):232.

32.

Pulmonary Artery Pseudoaneurysms: Clinical Features and CT Findings.

Chen Y, Gilman MD, Humphrey KL, Salazar GM, Sharma A, Muniappan A, Shepard JO, Wu CC.

AJR Am J Roentgenol. 2017 Jan;208(1):84-91. doi: 10.2214/AJR.16.16312. Epub 2016 Sep 22.

PMID:
27656954
33.

Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual Leukemia Cells.

Durfee PN, Lin YS, Dunphy DR, Muñiz AJ, Butler KS, Humphrey KR, Lokke AJ, Agola JO, Chou SS, Chen IM, Wharton W, Townson JL, Willman CL, Brinker CJ.

ACS Nano. 2016 Sep 27;10(9):8325-45. doi: 10.1021/acsnano.6b02819. Epub 2016 Jul 25.

PMID:
27419663
34.

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.

Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V.

Leukemia. 2016 Aug;30(8):1763-6. doi: 10.1038/leu.2016.41. Epub 2016 Mar 4. No abstract available.

35.

Reducing Pediatric Readmissions: Using a Discharge Bundle Combined With Teach-back Methodology.

Shermont H, Pignataro S, Humphrey K, Bukoye B.

J Nurs Care Qual. 2016 Jul-Sep;31(3):224-32. doi: 10.1097/NCQ.0000000000000176.

PMID:
26845419
36.

Expanding Horizons: A Pilot Mentoring Program Linking College/Graduate Students and Teens With ASD.

Curtin C, Humphrey K, Vronsky K, Mattern K, Nicastro S, Perrin EC.

Clin Pediatr (Phila). 2016 Feb;55(2):150-6. doi: 10.1177/0009922815588821. Epub 2015 May 27.

37.

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M.

Leukemia. 2015 Jul;29(7):1602-4. doi: 10.1038/leu.2015.14. Epub 2015 Jan 30. No abstract available.

PMID:
25634683
38.

To do or not to do: axillary nodal evaluation after ACOSOG Z0011 Trial.

Humphrey KL, Saksena MA, Freer PE, Smith BL, Rafferty EA.

Radiographics. 2014 Nov-Dec;34(7):1807-16. doi: 10.1148/rg.347130141. Review.

PMID:
25384280
39.

Percutaneous breast biopsy: effect on short-term quality of life.

Humphrey KL, Lee JM, Donelan K, Kong CY, Williams O, Itauma O, Halpern EF, Gerade BJ, Rafferty EA, Swan JS.

Radiology. 2014 Feb;270(2):362-8. doi: 10.1148/radiol.13130865. Epub 2013 Nov 11.

40.

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M.

N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.

41.

Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography.

Little BP, Gilman MD, Humphrey KL, Alkasab TK, Gibbons FK, Shepard JA, Wu CC.

AJR Am J Roentgenol. 2014 Jan;202(1):54-9. doi: 10.2214/AJR.13.10888.

PMID:
24370128
42.

Addition of tomosynthesis to conventional digital mammography: effect on image interpretation time of screening examinations.

Dang PA, Freer PE, Humphrey KL, Halpern EF, Rafferty EA.

Radiology. 2014 Jan;270(1):49-56. doi: 10.1148/radiol.13130765.

PMID:
24354377
43.

Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice.

Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, O'Gara C, McRobbie H, Humphrey K, Ali R, Strang J, Sutherland G.

Addiction. 2013 Dec;108(12):2193-201. doi: 10.1111/add.12304. Epub 2013 Aug 28.

44.

Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes.

Tario JD Jr, Humphrey K, Bantly AD, Muirhead KA, Moore JS, Wallace PK.

J Vis Exp. 2012 Dec 13;(70):e4287. doi: 10.3791/4287.

45.

Radiographic follow-up of suspected pneumonia: survey of Society of Thoracic Radiology membership.

Humphrey KL, Gilman MD, Little BP, Halpern EF, Abbott GF, Shepard JA, Wu CC.

J Thorac Imaging. 2013 Jul;28(4):240-3. doi: 10.1097/RTI.0b013e3182776c5e.

PMID:
23222200
46.

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.

Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, De Guibert S, Ritgen M, Langerak AW, Bieska G, Engelke A, Humphrey K, Wenger M, Hallek M.

Leukemia. 2013 Apr;27(5):1172-4. doi: 10.1038/leu.2012.252. Epub 2012 Aug 31. No abstract available.

PMID:
22936013
47.

Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension.

Minderman H, Humphrey K, Arcadi JK, Wierzbicki A, Maguire O, Wang ES, Block AW, Sait SN, George TC, Wallace PK.

Cytometry A. 2012 Sep;81(9):776-84. doi: 10.1002/cyto.a.22101. Epub 2012 Jul 26.

48.

Salience of the lambs: a test of the saliency map hypothesis with pictures of emotive objects.

Humphrey K, Underwood G, Lambert T.

J Vis. 2012 Jan 25;12(1). pii: 22. doi: 10.1167/12.1.22.

49.

Decisions about objects in real-world scenes are influenced by visual saliency before and during their inspection.

Underwood G, Humphrey K, van Loon E.

Vision Res. 2011 Sep 15;51(18):2031-8. doi: 10.1016/j.visres.2011.07.020. Epub 2011 Jul 26.

50.

The potency of people in pictures: evidence from sequences of eye fixations.

Humphrey K, Underwood G.

J Vis. 2010 Aug 19;10(10):19. doi: 10.1167/10.10.19.

Supplemental Content

Loading ...
Support Center